PMID- 29030251
OWN - NLM
STAT- MEDLINE
DCOM- 20180618
LR  - 20180621
IS  - 1879-0542 (Electronic)
IS  - 0165-2478 (Linking)
VI  - 192
DP  - 2017 Dec
TI  - Intravenous immunoglobulin (IVIG) treatment modulates peripheral blood Th17 and 
      regulatory T cells in recurrent miscarriage patients: Non randomized, open-label 
      clinical trial.
PG  - 12-19
LID - S0165-2478(17)30318-8 [pii]
LID - 10.1016/j.imlet.2017.10.003 [doi]
AB  - BACKGROUND: Th17 cells and Treg cells have been proposed as new risk factors for 
      recurrent miscarriage (RM). In this study, we investigated the effect of 
      Intravenous immunoglobulin G (IVIG) on the levels and function of Th17 and Treg 
      cells and pregnancy outcome in women with RM. MATERIALS AND METHODS: 94 pregnant 
      women with RM were enrolled in this study. Blood was drawn at the time of 
      positive pregnancy. On the same day, IVIG 400mg/kg was administered intravenously 
      for 44 patients. 50 other RM patients were included as no IVIG interfering 
      control group. Following the first administration, IVIG was given every 4 weeks 
      through 32 weeks of gestation. Peripheral blood was drawn after the last 
      administration (32 weeks after pregnancy). RESULTS: IVIG down-regulated Th17 
      cells population and function and up-regulated Treg cells population and function 
      were significant in the treated group. Pregnancy outcome in IVIG treated subjects 
      was successful in 38 out of 44 RM women (86.3%). However, pregnancy outcome was 
      successful in 21 out of 50 untreated RM women (42%). CONCLUSION: Administration 
      of IVIG in RM women with cellular immune cells abnormalities during pregnancy 
      influences Th17/Treg ratio in peripheral blood and enhances Treg and decreases 
      Th17 responses.
CI  - Copyright (c) 2017. Published by Elsevier B.V.
FAU - Ahmadi, Majid
AU  - Ahmadi M
AD  - Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical 
      Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of 
      Medical Sciences, Tabriz, Iran; Student's Research Committee, Tabriz University 
      of Medical Sciences, Tabriz, Iran; Department of Immunology, School of Medicine, 
      Tabriz University of Medical Sciences, Tabriz, Iran.
FAU - Aghdam, Sanaz Abbaspour
AU  - Aghdam SA
AD  - Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Nouri, Mohammad
AU  - Nouri M
AD  - Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical 
      Sciences, Tabriz, Iran; Reproductive Biology Department, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Babaloo, Zohreh
AU  - Babaloo Z
AD  - Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Farzadi, Laya
AU  - Farzadi L
AD  - Reproductive Biology Department, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Ghasemzadeh, Aliye
AU  - Ghasemzadeh A
AD  - Reproductive Biology Department, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Hamdi, Kobra
AU  - Hamdi K
AD  - Reproductive Biology Department, Tabriz University of Medical Sciences, Tabriz, 
      Iran.
FAU - Movassaghpour, Ali Akbar
AU  - Movassaghpour AA
AD  - Hematology and Oncology Research Center, Tabriz University of Medical Sciences, 
      Tabriz, Iran.
FAU - Jadidi-Niaragh, Farhad
AU  - Jadidi-Niaragh F
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Afkham, Amir
AU  - Afkham A
AD  - Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Motallebnezhad, Morteza
AU  - Motallebnezhad M
AD  - Stem Cell and Regenerative Medicine Institute, Tabriz University of Medical 
      Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of 
      Medical Sciences, Tabriz, Iran.
FAU - Eghbal-Fard, Shadi
AU  - Eghbal-Fard S
AD  - Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Dolati, Sanam
AU  - Dolati S
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran.
FAU - Younesi, Vahid
AU  - Younesi V
AD  - Pishtaz Teb Diagnostics, Tehran, Iran.
FAU - Yousefi, Mehdi
AU  - Yousefi M
AD  - Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, 
      Iran; Department of Immunology, School of Medicine, Tabriz University of Medical 
      Sciences, Tabriz, Iran. Electronic address: Yousefime@tbzmed.ac.ir.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20171010
PL  - Netherlands
TA  - Immunol Lett
JT  - Immunology letters
JID - 7910006
RN  - 0 (Cytokines)
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Abortion, Habitual/immunology/*therapy
MH  - Adult
MH  - Blood Cells/*immunology
MH  - Cytokines/genetics/metabolism
MH  - Female
MH  - Forkhead Transcription Factors/genetics/metabolism
MH  - Gene Expression Regulation
MH  - Humans
MH  - Immunoglobulins, Intravenous/*therapeutic use
MH  - Immunotherapy/*methods
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - T-Lymphocytes, Regulatory/*immunology
MH  - Th17 Cells/*immunology
OTO - NOTNLM
OT  - Intravenous immunoglobulin G
OT  - Recurrent miscarriage
OT  - Th17
OT  - Treg
EDAT- 2017/10/17 06:00
MHDA- 2018/06/19 06:00
CRDT- 2017/10/15 06:00
PHST- 2017/07/08 00:00 [received]
PHST- 2017/10/07 00:00 [revised]
PHST- 2017/10/09 00:00 [accepted]
PHST- 2017/10/17 06:00 [pubmed]
PHST- 2018/06/19 06:00 [medline]
PHST- 2017/10/15 06:00 [entrez]
AID - S0165-2478(17)30318-8 [pii]
AID - 10.1016/j.imlet.2017.10.003 [doi]
PST - ppublish
SO  - Immunol Lett. 2017 Dec;192:12-19. doi: 10.1016/j.imlet.2017.10.003. Epub 2017 Oct 
      10.